About Cyxone

Cyxone develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. Our goal is to improve the quality of life for patients in need of a more effective, convenient and safe treatment option.

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Our mission is to provide better therapies for patients suffering from autoimmune diseases

Press Releases

Cyxone AB announces last day of trading in BTA

August 26, 2024 14:19 (CEST)

Regulatory
Cyxone AB publishes outcome of rights issue

August 16, 2024 08:59 (CEST)

Regulatory
The subscription period in Cyxone’s rights issue starts today

August 1, 2024 08:45 (CEST)

Regulatory

About Cyxone

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

Multiple sclerosis (T20K)

Press Releases

Cyxone AB announces last day of trading in BTA

Cyxone AB publishes outcome of rights issue

The subscription period in Cyxone’s rights issue starts today

Subscribe to Press Releases